Stock Scorecard
Stock Summary for Taysha Gene Therapies Inc (TSHA) - $2.35 as of 4/25/2024 1:33:15 PM EST
Total Score
8 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for TSHA
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TSHA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TSHA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for TSHA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for TSHA
Financial Details for TSHA
Company Overview |
|
|---|---|
| Ticker | TSHA |
| Company Name | Taysha Gene Therapies Inc |
| Country | USA |
| Description | Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/9/2024 |
Stock Price History |
|
| Last Day Price | 2.35 |
| Last Day Price Updated | 4/25/2024 1:33:15 PM EST |
| Last Day Volume | 794,093 |
| Average Daily Volume | 3,135,076 |
| 52-Week High | 3.89 |
| 52-Week Low | 0.50 |
| Last Price to 52 Week Low | 370.00% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 61.03 |
| Sector PE | 61.73 |
| 5-Year Average PE | 0.63 |
| Free Cash Flow Ratio | 3.05 |
| Industry Free Cash Flow Ratio | 18.94 |
| Sector Free Cash Flow Ratio | 30.74 |
| Current Ratio Most Recent Quarter | 4.08 |
| Total Cash Per Share | 0.77 |
| Book Value Per Share Most Recent Quarter | 0.40 |
| Price to Book Ratio | 7.32 |
| Industry Price to Book Ratio | 7.50 |
| Sector Price to Book Ratio | 22.08 |
| Price to Sales Ratio Twelve Trailing Months | 35.59 |
| Industry Price to Sales Ratio Twelve Trailing Months | 9.51 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
| Total Shares Outstanding | 187,018,000 |
| Market Capitalization | 439,492,300 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 32.80% |
| Reported EPS 12 Trailing Months | -0.96 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | 0.13 |
| Net Income Twelve Trailing Months | -111,566,000 |
| Net Income Past Year | -111,566,000 |
| Net Income Prior Year | -166,014,000 |
| Quarterly Revenue Growth YOY | 44.00% |
| 5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 143,940,000 |
| Total Cash Past Year | 143,940,000 |
| Total Cash Prior Year | 87,880,000 |
| Net Cash Position Most Recent Quarter | 66,940,000 |
| Net Cash Position Past Year | 66,940,000 |
| Long Term Debt Past Year | 77,000,000 |
| Long Term Debt Prior Year | 37,967,000 |
| Total Debt Most Recent Quarter | 77,000,000 |
| Equity to Debt Ratio Past Year | 0.49 |
| Equity to Debt Ratio Most Recent Quarter | 0.49 |
| Total Stockholder Equity Past Year | 74,937,000 |
| Total Stockholder Equity Prior Year | 949,000 |
| Total Stockholder Equity Most Recent Quarter | 74,937,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.04 |
| MACD Signal | 0.03 |
| 20-Day Bollinger Lower Band | 0.99 |
| 20-Day Bollinger Middle Band | 2.17 |
| 20-Day Bollinger Upper Band | 3.34 |
| Beta | 0.26 |
| RSI | 46.84 |
| 50-Day SMA | 1.86 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 4/25/2024 1:33:16 PM EST |